TRPV1 regulates inflammatory process in the tongue of surgically induced xerostomia mouse
Min H. Yoo PhD
Department of Innovative Toxicology Research, Korea Institute of Toxicology, Daejeon, Republic of Korea
Search for more papers by this authorYun-Hee Rhee PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorJaeYun Jung MD, PhD
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorSang-Joon Lee MD, PhD
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorJung-Hwan Moon MD, PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorCorresponding Author
Ji-Hun Mo MD, PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Correspondence
Ji-Hun Mo and Phil-Sang Chung, Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea.
Email: [email protected] (J.-H. M.) and [email protected] (P.-S. C.)
Search for more papers by this authorCorresponding Author
Phil-Sang Chung MD, PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Correspondence
Ji-Hun Mo and Phil-Sang Chung, Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea.
Email: [email protected] (J.-H. M.) and [email protected] (P.-S. C.)
Search for more papers by this authorMin H. Yoo PhD
Department of Innovative Toxicology Research, Korea Institute of Toxicology, Daejeon, Republic of Korea
Search for more papers by this authorYun-Hee Rhee PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorJaeYun Jung MD, PhD
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorSang-Joon Lee MD, PhD
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorJung-Hwan Moon MD, PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Search for more papers by this authorCorresponding Author
Ji-Hun Mo MD, PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Correspondence
Ji-Hun Mo and Phil-Sang Chung, Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea.
Email: [email protected] (J.-H. M.) and [email protected] (P.-S. C.)
Search for more papers by this authorCorresponding Author
Phil-Sang Chung MD, PhD
Laser Translational Clinical Trial Center, Dankook University Hospital, Cheonan, Republic of Korea
Beckman Laser Institute Korea, Dankook University, Cheonan, Republic of Korea
Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan, Republic of Korea
Correspondence
Ji-Hun Mo and Phil-Sang Chung, Department of Otorhinolaryngology, College of Medicine, Dankook University, Cheonan 31116, Republic of Korea.
Email: [email protected] (J.-H. M.) and [email protected] (P.-S. C.)
Search for more papers by this authorFunding information: Ministry of Health & Welfare, Republic of Korea, Grant/Award Number: HI15C1524; Ministry of Education and Science Technology (MEST), Grant/Award Number: NRF-2016R1A2B4010407
Abstract
Background
The aim of study is to investigate the role of transient receptor potential cation channel subfamily V member 1 (TRPV1) on xerostomia-induced inflammatory response in vivo.
Methods
Parotid, submandibular, and lingual gland were removed for xerostomia induction. The expression of inflammatory cytokines, TRPV1, NFkB, and MAPK in xerostomia was evaluated and compared in both TRPV1 wild and knockout mice.
Results
The level of interleukin-6 (IL-6) and IL-17, neutrophil/CD4 T-cell infiltration, phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N terminal kinase, TRPV1, and the localization of NFkB were elevated in xerostomia-induced TRPV1 wild-type mice. In contrast, inflammatory cytokines and MAPK were decreased in xerostomia-induced TRPV1 knockout mice. TRPV1 antagonist treatment also reduced tongue ulceration, neutrophil/CD4+ T-cell expression, IL-6, and IL-17 in TRPV1 wild-type mice.
Conclusion
TRPV1 had a crucial role in modulating inflammation in xerostomia and targeting TRPV1 might be a promising therapeutic strategy for xerostomia.
Supporting Information
| Filename | Description |
|---|---|
| hed25980-sup-0001-FigureS1.tiffTIFF image, 434.8 KB | Figure S1 Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCE
- 1Bahar G, Feinmesser R, Shpitzer T, Popovtzer A, Nagler RM. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer. 2007; 109(1): 54-59.
- 2Tenovuo J. Antimicrobial function of human saliva—how important is it for oral health? Acta Odontol Scand. 1998; 56(5): 250-256.
- 3Humphrey SP, Williamson RT. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 2001; 85(2): 162-169.
- 4Mandel ID. The role of saliva in maintaining oral homeostasis. J Am Dent Assoc. 1989; 119(2): 298-304.
- 5Atkinson JC, Fox PC. Salivary gland dysfunction. Clin Geriatr Med. 1992; 8(3): 499-511.
- 6Solans R, Bosch JA, Galofre P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001; 42(5): 738-743.
- 7Nieuw Amerongen AV, Veerman EC. Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. Support Care Cancer. 2003; 11(4): 226-231.
- 8Napenas JJ, Brennan MT, Fox PC. Diagnosis and treatment of xerostomia (dry mouth). Odontology. 2009; 97(2): 76-83.
- 9Nederfors T, Isaksson R, Mornstad H, Dahlof C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population—relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol. 1997; 25(3): 211-216.
- 10Villa A, Polimeni A, Strohmenger L, Cicciu D, Gherlone E, Abati S. Dental patients' self-reports of xerostomia and associated risk factors. J Am Dent Assoc. 2011; 142(7): 811-816.
- 11Hahnel S, Schwarz S, Zeman F, Schafer L, Behr M. Prevalence of xerostomia and hyposalivation and their association with quality of life in elderly patients in dependence on dental status and prosthetic rehabilitation: a pilot study. J Dent. 2014; 42(6): 664-670.
- 12Banoczy J, Szabo L, Csiba A. Migratory glossitis. A clinical-histologic review of seventy cases. Oral Surg Oral Med Oral Pathol. 1975; 39(1): 113-121.
- 13Guimaraes AL, Correia-Silva Jde F, Diniz MG, Xavier GM, Horta MC, Gomez RS. Investigation of functional gene polymorphisms: IL-1B, IL-6 and TNFA in benign migratory glossitis in Brazilian individuals. J Oral Pathol Med. 2007; 36(9): 533-537.
- 14Kumar V, Neutrophils SA. Cinderella of innate immune system. Int Immunopharmacol. 2010; 10(11): 1325-1334.
- 15Tetley TD. Inflammatory cells and chronic obstructive pulmonary disease. Curr Drug Targets Inflamm Allergy. 2005; 4(6): 607-618.
- 16Tsuchiya T, Fukuda S, Hamada H, et al. Role of gamma delta T cells in the inflammatory response of experimental colitis mice. J Immunol. 2003; 171(10): 5507-5513.
- 17Huang J, Zhang X, McNaughton PA. Inflammatory pain: the cellular basis of heat hyperalgesia. Curr Neuropharmacol. 2006; 4(3): 197-206.
- 18Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 2000; 288(5464): 306-313.
- 19Devesa I, Planells-Cases R, Fernandez-Ballester G, Gonzalez-Ros JM, Ferrer-Montiel A, Fernandez-Carvajal A. Role of the transient receptor potential vanilloid 1 in inflammation and sepsis. J Inflamm Res. 2011; 4: 67-81.
- 20Fernandes ES, Liang L, Smillie SJ, et al. TRPV1 deletion enhances local inflammation and accelerates the onset of systemic inflammatory response syndrome. J Immunol. 2012; 188(11): 5741-5751.
- 21Yoshida A, Furube E, Mannari T, et al. TRPV1 is crucial for proinflammatory STAT3 signaling and thermoregulation-associated pathways in the brain during inflammation. Sci Rep. 2016; 6: 26088.
- 22Bertin S, Aoki-Nonaka Y, Lee J, et al. The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1. Gut. 2016; 66(9): 1584-1596.
- 23Schwartz ES, La JH, Scheff NN, Davis BM, Albers KM, Gebhart GF. TRPV1 and TRPA1 antagonists prevent the transition of acute to chronic inflammation and pain in chronic pancreatitis. J Neurosci. 2013; 33(13): 5603-5611.
- 24Samivel R, Kim DW, Son HR, et al. The role of TRPV1 in the CD4+ T cell-mediated inflammatory response of allergic rhinitis. Oncotarget. 2016; 7(1): 148-160.
- 25Weiss J, Zimmermann F. Tribromoethanol (Avertin) as an anaesthetic in mice. Lab Anim. 1999; 33(2): 192-193.
- 26McGarvey LP, Butler CA, Stokesberry S, et al. Increased expression of bronchial epithelial transient receptor potential vanilloid 1 channels in patients with severe asthma. J Allergy Clin Immunol. 2014; 133(3): 704-712 e704.
- 27Erriu M, Canargiu F, Orru G, Garau V, Montaldo C. Idiopathic atrophic glossitis as the only clinical sign for celiac disease diagnosis: a case report. J Med Case Reports. 2012; 6: 185.
- 28Reamy BV, Derby R, Bunt CW. Common tongue conditions in primary care. Am Fam Physician. 2010; 81(5): 627-634.
- 29Ursache M, Gradinaru I, Nechifor M, Cherciu-Ciubotaru B. Implications of xerostomia in oral dis-homeostasis. Rev Med Chir Soc Med Nat Iasi. 2006; 110(2): 432-437.
- 30Lynge Pedersen AM, Nauntofte B, Smidt D, Torpet LA. Oral mucosal lesions in older people: relation to salivary secretion, systemic diseases and medications. Oral Dis. 2015; 21(6): 721-729.
- 31Grushka M. Clinical features of burning mouth syndrome. Oral Surg Oral Med Oral Pathol. 1987; 63(1): 30-36.
- 32Liu B, Dion MR, Jurasic MM, Gibson G, Jones JA. Xerostomia and salivary hypofunction in vulnerable elders: prevalence and etiology. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 114(1): 52-60.
- 33Lamey PJ, Lamb AB. Prospective study of aetiological factors in burning mouth syndrome. Br Med J (Clin Res Ed). 1988; 296(6631): 1243-1246.
- 34Schaible HG. Nociceptive neurons detect cytokines in arthritis. Arthritis Res Ther. 2014; 16(5): 470.
- 35Pappu R, Ramirez-Carrozzi V, Ota N, Ouyang W, Hu Y. The IL-17 family cytokines in immunity and disease. J Clin Immunol. 2010; 30(2): 185-195.
- 36Segond von Banchet G, Boettger MK, Konig C, Iwakura Y, Brauer R, Schaible HG. Neuronal IL-17 receptor upregulates TRPV4 but not TRPV1 receptors in DRG neurons and mediates mechanical but not thermal hyperalgesia. Mol Cell Neurosci. 2013; 52: 152-160.
- 37Flynn R, Chapman K, Iftinca M, Aboushousha R, Varela D, Altier C. Targeting the transient receptor potential vanilloid type 1 (TRPV1) assembly domain attenuates inflammation-induced hypersensitivity. J Biol Chem. 2014; 289(24): 16675-16687.
- 38Zhang F, Yang H, Wang Z, et al. Transient receptor potential vanilloid 1 activation induces inflammatory cytokine release in corneal epithelium through MAPK signaling. J Cell Physiol. 2007; 213(3): 730-739.
- 39Gavva NR, Treanor JJ, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain. 2008; 136(1–2): 202-210.
- 40Jaaskelainen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol. 2012; 123(1): 71-77.
Citing Literature
